Yue Zhang

Yue Zhang

Shenyang Medical College,Tsinghua University, China

Title: Post-transcriptional regulation of the tissue inhibitor of metalloproteinase-3 gene


Yue Zhang has completed his Ph.D at the age of 35 years from University of East Anglia and postdoctoral studies from Tsinghua University School of Biology. He is the associate professor of ShenYang Medical College. He has published more than 12 papers.


Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a major regulator of extracellular matrix degradation, cell signalling and apoptosis via control of the activities of the matrix metalloproteinases (MMPs) and adamalysinmetalloproteinases (ADAMs). TIMP3 gene plays an important role in cardiac remodeling.Deficiency of TIMP3 expression is frequently found in human cancers and heart failure. Dysregulation of microRNAs and the RNA binding protein HuR have also been linked to disease pathogenesis. However, the functions of miRNAs, AU-rich elements and HuR in regulating TIMP3 expression remain largely unknown.
My results provide evidence TIMP3 is regulated post-transcriptionally directly via its 3’-UTR. The presence of negative regulatory elements in the mouse Timp3 3’-UTR was indicated. Further analysis revealed a target site of miR-1in the TIMP3 3’-UTR. MiR-1 was shown to effectively decrease TIMP3 mRNA and protein expression.miR-21 inhibited TIMP3 mRNA expression via a highly conserved target site. Endogenous miR-21 is commonly upregulated in cancers. The fact that oncogenic miR-21 regulates the apoptosis-related gene TIMP3 suggests a novel mechanism contributing to TIMP3 silencing and may offer a partial explanation of the anti-apoptotic effect of miR-21.
In conclusion, this study investigated the role of cis-elements (AU-rich elements, miRNA target sites and conserved regions) and trans-acting factors (ARE binding protein HuR, miRNAs) in regulating TIMP3 post-transcriptional regulation. Identification of the functions of these factors in the regulation of TIMP3 gene expression may identify new targets for therapeutic intervention in cancer and other diseases.